CD34 and myocardial infarction: PreSERVE-AMI, a large clinical trial using CD34+ cell therapy for left ventricular dysfunction post-ST-segment elevation MI (STEMI), demonstrated the safety and potential efficacy of the intracoronary infusion of CD34+ cell therapy in post-MI patients [20].